Standard treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL) frequently includes monoclonal anti-CD20 antibodies (eg, rituximab and obinutuzumab), which deplete B-cells for at least 6–9 months.14,15 B-cell depletion could compromise adaptive antiviral immune responses, delay viral clearance, and prolong viral shedding16–18 and lead to more severe disease course, higher risk of re-infection, and prolonged infectivity.19–23. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.